131.22 0.00 (0.00%)
After hours: 5:12PM EST
|Bid||131.30 x 2900|
|Ask||131.36 x 800|
|Day's range||131.00 - 147.32|
|52-week range||19.31 - 189.26|
|Beta (5Y monthly)||1.50|
|PE ratio (TTM)||N/A|
|Earnings date||05 May 2021 - 10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||168.85|
Promising clinical trial data bodes well for the biotech's potential entry into the U.S. coronavirus vaccine market.
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
What happened Shares of Moderna (NASDAQ: MRNA) were sinking 7.2% lower as of 12:03 p.m. EST on Wednesday. It marked the second consecutive day of declines for the stock this week. One likely reason behind Moderna's pullback is the entrance of a new rival in the U.